Literature DB >> 23194425

Unsymmetric mono- and dinuclear platinum(IV) complexes featuring an ethylene glycol moiety: synthesis, characterization, and biological activity.

Verena Pichler1, Petra Heffeter, Seied M Valiahdi, Christian R Kowol, Alexander Egger, Walter Berger, Michael A Jakupec, Mathea Sophia Galanski, Bernhard K Keppler.   

Abstract

Eight novel mononuclear and two dinuclear platinum(IV) complexes were synthesized and characterized by elemental analysis, one- and two-dimensional NMR spectroscopy, mass spectrometry, and reversed-phase HPLC (log k(w)) and in one case by X-ray diffraction. Cytotoxicity of the compounds was studied in three human cancer cell lines (CH1, SW480, and A549) by means of the MTT assay, featuring IC(50) values to the low micromolar range. Furthermore a selected set of compounds was investigated in additional cancer cell lines (P31 and P31/cis, A2780 and A2780/cis, SW1573, 2R120, and 2R160) with regard to their resistance patterns, offering a distinctly different scheme compared to cisplatin. To gain further insights into the mode of action, drug uptake, DNA synthesis inhibition, cell cycle effects, and induction of apoptosis were determined for two characteristic substances.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23194425      PMCID: PMC4021451          DOI: 10.1021/jm301645g

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  48 in total

1.  In vitro studies on the mechanisms of oxaliplatin resistance.

Authors:  S Hector; W Bolanowska-Higdon; J Zdanowicz; S Hitt; L Pendyala
Journal:  Cancer Chemother Pharmacol       Date:  2001-11       Impact factor: 3.333

2.  Advances in platinum chemotherapeutics.

Authors:  Benjamin W Harper; Anwen M Krause-Heuer; Maxine P Grant; Madhura Manohar; K Benjamin Garbutcheon-Singh; Janice R Aldrich-Wright
Journal:  Chemistry       Date:  2010-06-25       Impact factor: 5.236

3.  The status of platinum anticancer drugs in the clinic and in clinical trials.

Authors:  Nial J Wheate; Shonagh Walker; Gemma E Craig; Rabbab Oun
Journal:  Dalton Trans       Date:  2010-06-30       Impact factor: 4.390

4.  Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes.

Authors:  Michael R Reithofer; Anna K Bytzek; Seied M Valiahdi; Christian R Kowol; Michael Groessl; Christian G Hartinger; Michael A Jakupec; Markus Galanski; Bernhard K Keppler
Journal:  J Inorg Biochem       Date:  2010-10-01       Impact factor: 4.155

Review 5.  Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches.

Authors:  Markus Galanski; Michael A Jakupec; Bernhard K Keppler
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

Review 6.  Basis for design and development of platinum(IV) anticancer complexes.

Authors:  Matthew D Hall; Howard R Mellor; Richard Callaghan; Trevor W Hambley
Journal:  J Med Chem       Date:  2007-06-28       Impact factor: 7.446

7.  Calculation of lipophilicity of a large, diverse dataset of anticancer platinum complexes and the relation to cellular uptake.

Authors:  Steven P Oldfield; Matthew D Hall; James A Platts
Journal:  J Med Chem       Date:  2007-09-27       Impact factor: 7.446

8.  Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin.

Authors:  Shinobu Matsumoto; Toshiko Tanaka; Hideo Kurokawa; Koji Matsuno; Yutaka Hayashida; Tetsu Takahashi
Journal:  Anticancer Res       Date:  2007 Jul-Aug       Impact factor: 2.480

Review 9.  Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution.

Authors:  Klára Valkó
Journal:  J Chromatogr A       Date:  2004-05-28       Impact factor: 4.759

Review 10.  Tumour-inhibiting platinum complexes--state of the art and future perspectives.

Authors:  M A Jakupec; M S Galanski; B K Keppler
Journal:  Rev Physiol Biochem Pharmacol       Date:  2003-02-04       Impact factor: 7.500

View more
  8 in total

Review 1.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

2.  Monofunctional and higher-valent platinum anticancer agents.

Authors:  Timothy C Johnstone; Justin J Wilson; Stephen J Lippard
Journal:  Inorg Chem       Date:  2013-06-05       Impact factor: 5.165

3.  Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes.

Authors:  Helena Henke; Kushtrim Kryeziu; Jelena Banfić; Sarah Theiner; Wilfried Körner; Oliver Brüggemann; Walter Berger; Bernhard K Keppler; Petra Heffeter; Ian Teasdale
Journal:  Macromol Biosci       Date:  2016-05-12       Impact factor: 4.979

4.  An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo.

Authors:  Josef Mayr; Petra Heffeter; Diana Groza; Luis Galvez; Gunda Koellensperger; Alexander Roller; Beatrix Alte; Melanie Haider; Walter Berger; Christian R Kowol; Bernhard K Keppler
Journal:  Chem Sci       Date:  2016-12-15       Impact factor: 9.825

5.  EGFR-targeting peptide-coupled platinum(IV) complexes.

Authors:  Josef Mayr; Sonja Hager; Bettina Koblmüller; Matthias H M Klose; Katharina Holste; Britta Fischer; Karla Pelivan; Walter Berger; Petra Heffeter; Christian R Kowol; Bernhard K Keppler
Journal:  J Biol Inorg Chem       Date:  2017-04-12       Impact factor: 3.358

6.  Highly and Broad-Spectrum In Vitro Antitumor Active cis-Dichloridoplatinum(II) Complexes with 7-Azaindoles.

Authors:  Pavel Štarha; Zdeněk Dvořák; Zdeněk Trávníček
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

7.  Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action.

Authors:  Raji Raveendran; Jeremy Phillip Braude; Ezequiel Wexselblatt; Vojtech Novohradsky; Olga Stuchlikova; Viktor Brabec; Valentina Gandin; Dan Gibson
Journal:  Chem Sci       Date:  2016-01-15       Impact factor: 9.825

8.  Multi-scale imaging of anticancer platinum(iv) compounds in murine tumor and kidney.

Authors:  A A Legin; S Theiner; A Schintlmeister; S Reipert; P Heffeter; M A Jakupec; J Mayr; H P Varbanov; C R Kowol; M Galanski; W Berger; M Wagner; B K Keppler
Journal:  Chem Sci       Date:  2016-02-03       Impact factor: 9.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.